Recruitment and Baseline Characteristics of Participants in the AgeWell.de Study-A Pragmatic Cluster-Randomized Controlled Lifestyle Trial against Cognitive Decline.
AgeWell.de
RCT
cluster-randomized controlled trial
cognitive function
dementia
general practitioner
intervention
lifestyle
prevention
primary care
trial
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
07 01 2021
07 01 2021
Historique:
received:
25
11
2020
revised:
02
01
2021
accepted:
05
01
2021
entrez:
12
1
2021
pubmed:
13
1
2021
medline:
15
1
2021
Statut:
epublish
Résumé
Targeting dementia prevention, first trials addressing multiple modifiable risk factors showed promising results in at-risk populations. In Germany, AgeWell.de is the first large-scale initiative investigating the effectiveness of a multi-component lifestyle intervention against cognitive decline. We aimed to investigate the recruitment process and baseline characteristics of the AgeWell.de participants to gain an understanding of the at-risk population and who engages in the intervention. General practitioners across five study sites recruited participants (aged 60-77 years, Cardiovascular Risk Factors, Aging, and Incidence of Dementia/CAIDE dementia risk score ≥ 9). Structured face-to-face interviews were conducted with eligible participants, including neuropsychological assessments. We analyzed group differences between (1) eligible vs. non-eligible participants, (2) participants vs. non-participants, and (3) between intervention groups. Of 1176 eligible participants, 146 (12.5%) dropped out before baseline; the study population was thus 1030 individuals. Non-participants did not differ from participants in key sociodemographic factors and dementia risk. Study participants were M = 69.0 (SD = 4.9) years old, and 52.1% were women. The average Montreal Cognitive Assessment/MoCA score was 24.5 (SD = 3.1), indicating a rather mildly cognitively impaired study population; however, 39.4% scored ≥ 26, thus being cognitively unimpaired. The bandwidth of cognitive states bears the interesting potential for differential trial outcome analyses. However, trial conduction is impacted by the COVID-19 pandemic, requiring adjustments to the study protocol with yet unclear methodological consequences.
Identifiants
pubmed: 33430189
pii: ijerph18020408
doi: 10.3390/ijerph18020408
pmc: PMC7825589
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Pragmatic Clinical Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : German Federal Ministry for Education and Research (BMBF)
ID : 01GL1704A, 01GL1704B, 01GL1704C, 01GL1704D, 01GL1704E, 01GL1704F
Pays : International
Références
J Affect Disord. 2018 Jan 15;226:28-35
pubmed: 28942203
Lancet. 2015 Jun 6;385(9984):2255-63
pubmed: 25771249
Br J Psychiatry. 1973 Oct;123(575):467-70
pubmed: 4748864
Alzheimer Dis Assoc Disord. 2009 Jul-Sep;23(3):198-204
pubmed: 19812459
Alzheimers Dement. 2020 Jul;16(7):1078-1094
pubmed: 32627328
J Affect Disord. 2007 Apr;99(1-3):203-11
pubmed: 17055064
Front Psychiatry. 2020 May 04;11:330
pubmed: 32431627
Lancet. 2020 Aug 8;396(10248):413-446
pubmed: 32738937
Int J Environ Res Public Health. 2014 Sep 10;11(9):9345-60
pubmed: 25211775
Neuroepidemiology. 2013;41(1):35-41
pubmed: 23712106
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):786-94
pubmed: 23703499
Lancet Neurol. 2017 May;16(5):377-389
pubmed: 28359749
J Child Psychol Psychiatry. 2001 Feb;42(2):241-51
pubmed: 11280420
Nutr J. 2010 Sep 14;9:36
pubmed: 20840739
Gerontologist. 2006 Aug;46(4):503-13
pubmed: 16921004
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):802-8
pubmed: 23703501
BMC Geriatr. 2019 Aug 1;19(1):203
pubmed: 31370792
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):650-5
pubmed: 23703482
J Gerontol B Psychol Sci Soc Sci. 2018 Apr 16;73(suppl_1):S20-S28
pubmed: 29669097
Arch Neurol. 2007 Sep;64(9):1323-9
pubmed: 17846273
Md State Med J. 1965 Feb;14:61-5
pubmed: 14258950
Neurology. 1989 Sep;39(9):1159-65
pubmed: 2771064
J Alzheimers Dis. 2018;64(1):71-78
pubmed: 29865075
Neurology. 2020 Aug 4;95(5):e519-e531
pubmed: 32611641
Nervenarzt. 2001 Mar;72(3):196-203
pubmed: 11268764
Psychopharmacol Bull. 1988;24(4):641-52
pubmed: 3249766
Clin Epidemiol. 2018 Sep 18;10:1233-1247
pubmed: 30271219
Am J Psychiatry. 1984 Nov;141(11):1356-64
pubmed: 6496779
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Arch Clin Neuropsychol. 1999 Feb;14(2):167-77
pubmed: 14590600
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):795-801
pubmed: 23703500
J Alzheimers Dis. 2018;64(2):643-655
pubmed: 29945351
Lancet. 2016 Aug 20;388(10046):797-805
pubmed: 27474376
Nat Rev Neurol. 2018 Nov;14(11):653-666
pubmed: 30291317